Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

bone metastases lenvatinib liver metastases lung metastases pembrolizumab renal cell carcinoma sarcomatoid histology sunitinib

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 22 11 2023
accepted: 27 11 2023
medline: 18 3 2024
pubmed: 18 3 2024
entrez: 18 3 2024
Statut: epublish

Résumé

[This corrects the article DOI: 10.3389/fonc.2023.1223282.].

Identifiants

DOI: 10.3389/fonc.2023.1343027 PMID: 38495081 PMC: PMC10941979
pubmed: 38495081
doi: 10.3389/fonc.2023.1343027
pmc: PMC10941979
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1343027

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright © 2024 Grünwald, Powles, Eto, Kopyltsov, Rha, Porta, Motzer, Hutson, Méndez-Vidal, Hong, Winquist, Goh, Maroto, Buchler, Takagi, Burgents, Perini, He, Okpara, McKenzie and Choueiri.

Auteurs

Viktor Grünwald (V)

Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany.

Thomas Powles (T)

Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom.

Masatoshi Eto (M)

Department of Urology, Kyushu University, Fukuoka, Japan.

Evgeny Kopyltsov (E)

State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.

Sun Young Rha (SY)

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.

Camillo Porta (C)

Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy.

Robert Motzer (R)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Thomas E Hutson (TE)

Medical Oncology, Texas Oncology, Dallas, TX, United States.

María José Méndez-Vidal (MJ)

Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain.

Sung-Hoo Hong (SH)

Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

Eric Winquist (E)

Department of Oncology, University of Western Ontario, London, ON, Canada.

Jeffrey C Goh (JC)

ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia.

Pablo Maroto (P)

Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Tomas Buchler (T)

Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia.

Toshio Takagi (T)

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Joseph E Burgents (JE)

Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States.

Rodolfo Perini (R)

Clinical Research, Merck & Co., Inc., Rahway, NJ, United States.

Cixin He (C)

Biostatistics, Eisai Inc., Nutley, NJ, United States.

Chinyere E Okpara (CE)

Clinical Research, Eisai Ltd., Hatfield, United Kingdom.

Jodi McKenzie (J)

Clinical Research, Eisai Inc., Nutley, NJ, United States.

Toni K Choueiri (TK)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Classifications MeSH